Iron overload. More than hereditary hemochromatosis;Sobrecarga férrica. Algo más que hemocromatosis hereditaria

Medicina Clinica

Volumn 120, Issue 18, 2003, Pages 704-706

  Altés Hernández, Albert ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN; RIBONUCLEOTIDE REDUCTASE;

EDITORIAL; GENE IDENTIFICATION; GENE MUTATION; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; IRON METABOLISM; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTOR; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; THROMBOEMBOLISM;

EID: 0038451550     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13047697     Document Type: Editorial

References (43)

1. Bonkovsky HL, Ponka P, Bacon BR, Drysdale J, Grace ND, Tavill AS. An Update on iron metabolism: summary of the fifth international conference on disorders of iron metabolism. Hepatology 1996;24:718-29.
2. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Gen 1996;13:399-408.
3. Pérez-Aguilar F. Hemocromatosis hereditaria: consideraciones fisiopatológicas, clinicas y terapéuticas. Med Clin (Barc) 2002;118:103-10.
4. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
5. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5.
6. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001;28:213-4.
7. Camaschella C, Roetto A, De Gobbi M. Genetic haemochromatosis: genes and mutations associated with iron loading. Best Practice&Research Clinical Haematology 2002;15:261-76.
8. Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB, Wilson PW, et al. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001;73:638-46.
9. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary haemochromatosis. Gastroenterology 1996;110:1107-19.
10. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF Jr. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-2.
11. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. P53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 1999;117:154-60.
12. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-66.
13. Stevens RG, Jones I, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. New Engl J Med 1988;318:1047-52.
14. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-9.
15. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliövaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-82.
16. Selby JV, Friedman GD. Epidemiologic evidence of an association between body iron stores and risk of cancer. Int J Cancer 1988;41:677-82.
17. Nelson RL, Davis FG, Sutter E, Sobin LH, Kikendall JW, Bowen Ph. Body iron stores and risk of colonic neoplasia. J Nat Cancer Institute 1994;86:455-60.
18. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst 2003;95:154-9.
19. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ 1997;314:793-4.
20. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
21. Tuomainen TP, Punnonen K, Nyyssönen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998;97:1461-6.
22. Gillum RF. Body iron stores and atherosclerosis. Circulation 1997;96: 3261-3.
23. Roest M, van der Schouw YT, Valk B, Marx JM, Tempelman MJ, Groot PG, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999;100:1268-73.
24. Tuomainen T, Kontula K, Nyyssonen K, Lakka TA, Helic, T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation. A prospective cohort study in men in eastern Finland. Circulation 1999;100:1274-9.
25. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001;154:739-46.
26. Dávalos A, Castillo J, Marrugat J, Fernández-Real JM, Armengou A, Cacabelos P, et al. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 2000;54:1568-74.
27. Xie YG, Lillicrap D. An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis. Blood 1998;92:1461-2.
28. Altés A, Remacha AF, Sureda A, Martino R, Briones J, Brunet S, et al. Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. Ann Hematol 2003;82:127-30.
29. Hezode Ch, Cazeneuve C, Coue O, Roudot-Thoraval F, Lonjon I, Bastie A, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-84.
30. Remacha AF, Carrasco M, Sarda MP, Barceló MJ, Baiget M. HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload. Haematologica 1999;84:284-5.
31. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-52.
32. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002;37:848-54.
33. Casañas R, Scharfetter H, Altés A, Rosell J. Magnetic induction system for the non-invasive measurement of susceptibility and conductivity of biological tissues. Oslo, Noruega: XI Conference in Electrical Bio-Impedance, junio 2001.
34. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-7.
35. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
36. Olivieri NF, Brittenham GM. Iron-Chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
37. Franchini M, Gandini G, Gironcoli M, Vassanelli A, Borgna-Pignatti B, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000;95:2776-9.
38. Gregorio FD, Romeo MA, Pizzarelli G, Aiello G, Russo G. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients. Br J Haematol 1997;98:601-2.
39. Carmine TC, Evans P, Bruchelt G. Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Lett 1995;94:219-26.
40. Bradley S, Gosriwitana I, Srichairatanakool S, Hider R, Porter J. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997;99:337-43.
41. Altés A, Remacha A, Sureda A, Martino R, Briones J, Brunet S, et al. Iron overload might increase TRIM in haematopoietic stem cell transplantation. Bone Marrow Transplantation 2002;29:987-9.
42. Castillo A, Portugal J. Hemocromatosis hereditaria: consideraciones y propuestas. Med Clin (Barc) 2002;119:436-7.
43. Página web de la Asociación Española de Hemocromatosis: http://www. geocities.com/HotSprings/Villa/1284